Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) CFO David S. Snyder purchased 1,800 shares of the company's stock in a transaction that occurred on Thursday, November 14th. The stock was acquired at an average cost of $7.19 per share, for a total transaction of $12,942.00. Following the transaction, the chief financial officer now owns 8,800 shares in the company, valued at $63,272. This represents a 25.71 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Coya Therapeutics Trading Down 2.3 %
NASDAQ:COYA traded down $0.16 on Friday, hitting $6.65. The stock had a trading volume of 8,696 shares, compared to its average volume of 71,443. Coya Therapeutics, Inc. has a 1 year low of $4.75 and a 1 year high of $10.69. The firm's fifty day simple moving average is $7.11 and its two-hundred day simple moving average is $7.01.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15. On average, equities analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Coya Therapeutics
Top "Sleeping Giant" Crypto In The Market Now
From Crypto 101 Media | Ad
Top "Sleeping Giant" Crypto In The Market Now
We're looking at potential returns that could rewrite your financial future.
Click here to discover our #1 crypto pick before it's too late
A number of hedge funds and other institutional investors have recently made changes to their positions in COYA. Vanguard Group Inc. raised its position in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company's stock worth $8,407,000 after acquiring an additional 750,338 shares during the period. Gilbert & Cook Inc. purchased a new stake in shares of Coya Therapeutics during the 2nd quarter worth approximately $61,000. Renaissance Technologies LLC bought a new stake in shares of Coya Therapeutics in the 2nd quarter worth approximately $101,000. Finally, GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics in the third quarter valued at approximately $169,000. 39.75% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts have recently commented on COYA shares. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday. Chardan Capital reissued a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Thursday, November 7th.
View Our Latest Report on Coya Therapeutics
Coya Therapeutics Company Profile
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
